CEO Address:
I am excited
CEO Address:
|
 |
|
I am excited to report that OncoSec is continuing to execute on the corporate milestones which were set in the beginning of 2012 .
We have just announced positive preliminary efficacy and safety results for patients who are still undergoing treatment in our Merkel cell carcinoma (MCC) program. One patient with progressive MCC who had no success with any past treatments, showed a 70% regression in tumors (including distant tumors). You can find out more about MCC and why this data is significant to our company on our blog .
In addition, we will host the first symposium for ImmunoPulse at the prestigious European Association of Dermato-Oncology (EADO) Congress on November 14-17. At this meeting, early data will also be presented for the first time on our ongoing Phase II metastatic melanoma program.
Looking ahead, we see some potentially exciting catalysts that will continue to build value for our shareholders and advance our programs to commercialization. Again, thank you for being a vital part of providing a new hope for people dealing with advanced stage skin cancer and your continued support of our progress at OncoSec.
Punit Dhillon
|
OncoSec Medical Incorporated (ONCS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Strength Training at the Core of Fitness Trends As the world embraces a new year, the fitness landscape is evolving significantly. The traditional approach of engaging primarily in cardio exercises to reach health goals is being left behind. This year, individuals are increasingly recognizing the myriad benefits of strength training. It has become the foundation upon...
Continue Reading
Armor Health Partners with CCNO to Enhance Care Services Armor Health, a leader in integrated correctional healthcare, has successfully taken over health services at the Corrections Center of Northwest Ohio. The transition marks a significant step for both the facility and Armor Health, ensuring that all correctional healthcare needs are met efficiently and...
Continue Reading
Preparing for Twist Bioscience's Earnings Announcement Twist Bioscience (NASDAQ: TWST) is set to reveal its quarterly earnings report soon, creating significant anticipation among investors. This article will provide a comprehensive overview in anticipation of this crucial financial announcement. Market Expectations and Earnings Predictions Analysts project that Twist...
Continue Reading
Insight into Snap's Recent Options Activity Investors are showing a strong bullish sentiment towards Snap (NYSE: SNAP), and this trend is something market watchers should pay attention to. Our thorough review of public option flows reveals significant trading patterns that often signal imminent market changes. We've observed an unparalleled surge in Snap options trading,...
Continue Reading
Canada's Consideration of Retaliatory Tariffs Discussions are taking place in Canada regarding the imposition of retaliatory tariffs targeting a variety of U.S. goods, with orange juice being prominently mentioned. This potential move arises in response to the threat of a significant 25% tariff on imports from Canada, as suggested by newly elected officials in the United...
Continue Reading
